Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

RusHydro plans to increase the number of electric filling stations to 1,500 by 2035

3/2/23 HYDR

Sberbank launched acquiring for stores in the Crimea and Sevastopol

3/2/23 SBER

MTS gradually shuts down 3G networks, freeing up frequencies for 4G

3/2/23 MTSS

Felix Evtushenkov assessed prospects of Binnopharm Group's IPO

3/2/23 AFKS

Lukoil organized raid transshipment of Urals oil near Kaliningrad

3/2/23 LKOH

RusHydro will move its head office to the Krasnoyarsk Territory

3/2/23 HYDR

Nizhnekamskneftekhim is commissioning three lines after the fire in the Rubber Separation Shop

3/2/23 NKNC

Salesforce's profits have dropped sevenfold

3/2/23 CRM

Rostelecom acquired developer of antifraud system Fuzzy Logic Labs

3/1/23 RTKM

MKB issued the first digital bank guarantee in yuan

3/1/23 CBOM